Log In
BCIQ
Print this Print this
 

ProstaScint, Protascint, III-indium capromab pendetide

  Manage Alerts
Collapse Summary General Information
Company Aytu BioScience Inc.
DescriptionRadiolabeled mAb that recognizes prostate-specific membrane antigen (PSMA)
Molecular Target Prostate-specific membrane antigen (PSMA) (FOLH1) (GCPII)
Mechanism of ActionDiagnostic; Imaging agent; Radiolabelled antibody
Therapeutic ModalityDiagnostics: Radiologic imaging
Latest Stage of DevelopmentMarketed
Standard IndicationCancer, Diagnostic
Indication DetailsDetect metastases and extent of prostate cancer; Detect prostate cancer; Detect recurrent prostate cancer; Diagnose recurrent prostate cancer; Guide targeted radiation therapy for prostate cancer; Identify prostate cancer with high risk spreading; Identify recurrent prostate cancer; Imaging to detect recurrence of prostate tumors; Predict response of prostate cancer to radiotherapy; Predict which patients are less likely to benefit from brachytherapy for prostate cancer
Regulatory Designation
PartnerAytu BioScience Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$1.7M

$1.7M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

06/09/2015

$1.7M

$1.7M

0

Get a free BioCentury trial today